These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 22077677)

  • 1. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
    Cho YT; Chen CH; Chiu HY; Tsai TF
    J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
    Chung SJ; Kim JK; Park MC; Park YB; Lee SK
    J Rheumatol; 2009 Nov; 36(11):2416-20. PubMed ID: 19797507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
    Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
    Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease.
    Cassano N; Mastrandrea V; Principi M; Loconsole F; De Tullio N; Di Leo A; Vena GA
    J Biol Regul Homeost Agents; 2011; 25(2):285-9. PubMed ID: 21880218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis.
    Navarro R; Concha-Garzón MJ; Castaño C; Casal C; Guiu A; Daudén E
    Int J Dermatol; 2014 Jul; 53(7):909-11. PubMed ID: 24673290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
    Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI
    Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases.
    Kim YJ; Bae SC; Sung YK; Kim TH; Jun JB; Yoo DH; Kim TY; Sohn JH; Lee HS
    J Rheumatol; 2010 Feb; 37(2):346-50. PubMed ID: 20008922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
    Navarro R; Vilarrasa E; Herranz P; Puig L; Bordas X; Carrascosa JM; Taberner R; Ferrán M; García-Bustinduy M; Romero-Maté A; Pedragosa R; García-Diez A; Daudén E
    Br J Dermatol; 2013 Mar; 168(3):609-16. PubMed ID: 22985451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.
    Caporali R; Bobbio-Pallavicini F; Atzeni F; Sakellariou G; Caprioli M; Montecucco C; Sarzi-Puttini P
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):749-54. PubMed ID: 20535784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
    Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P
    J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB; Bond MI
    Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.
    Chiu HY; Chen CH; Wu MS; Cheng YP; Tsai TF
    Br J Dermatol; 2013 Dec; 169(6):1295-303. PubMed ID: 23746170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database.
    Sanz-Bueno J; Vanaclocha F; García-Doval I; Torrado R; Carretero G; Daudén E; Patricia Ruiz-Genao D; Alsina-Gibert MM; Pérez-Zafrilla B; Pérez-Rial G; Rivera R;
    Actas Dermosifiliogr; 2015; 106(6):477-82. PubMed ID: 25776200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.
    Biondo MI; Germano V; Pietrosanti M; Canzoni M; Marignani M; Stroffolini T; Salemi S; D'Amelio R
    Eur J Intern Med; 2014 Jun; 25(5):482-4. PubMed ID: 24495663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.
    Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
    Rheumatology (Oxford); 2006 Oct; 45(10):1294-7. PubMed ID: 16603583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.
    Megna M; Patruno C; Bongiorno MR; Gambardella A; Guarneri C; Romita P; Raimondo A; Loconsole F; Fabbrocini G
    Clin Drug Investig; 2022 Jun; 42(6):525-531. PubMed ID: 35633470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept).
    Cecchi R; Bartoli L
    Dermatol Online J; 2006 Dec; 12(7):4. PubMed ID: 17459290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment.
    Nordgaard-Lassen I; Dahlerup JF; Belard E; Gerstoft J; Kjeldsen J; Kragballe K; Ravn P; Sørensen IJ; Theede K; Tjellesen L;
    Dan Med J; 2012 Jul; 59(7):C4480. PubMed ID: 22759856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.
    Chiu HY; Hsueh PR; Tsai TF
    Br J Dermatol; 2011 Mar; 164(3):553-9. PubMed ID: 21083541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.